{"id":16874,"date":"2017-02-07T13:37:56","date_gmt":"2017-02-07T12:37:56","guid":{"rendered":"http:\/\/mabdesign.fr\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/"},"modified":"2017-02-07T13:37:56","modified_gmt":"2017-02-07T12:37:56","slug":"acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/","title":{"rendered":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017"},"content":{"rendered":"<p><span style=\"color: #009c9b;\"><a style=\"color: #009c9b;\" href=\"https:\/\/acticor-biotech.com\/\" target=\"_blank\" rel=\"noopener\"><strong>Acticor Biotech<\/strong><\/a><\/span>, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised \u20ac1,5M from CapDecisif Management. Acticor Biotech had already secured \u20ac1,4M in the first closing, which brings the total amount invested to \u20ac2,9M.<\/p>\n<p>This new fund will enable Acticor Biotech to pursue the development of its lead candidate ACT017 in Acute Ischemic Stroke, toward its entry in Phase I Clinical Trial.<\/p>\n<p>Thanks to encouraging pre-clinical results and positive regulatory meetings, Acticor Biotech should start its Phase I 6 months earlier than originally planned. The first subject could thus be scheduled for early Q4 2017.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><span style=\"text-decoration: underline; color: #009c9b;\"><a style=\"color: #009c9b; text-decoration: underline;\" href=\"https:\/\/acticor-biotech.com\/acticor-biotech-secures-e15m-new-funding-from-capdecisif-management\/\" target=\"_blank\" rel=\"noopener\">Read more<\/a><\/span><\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017, for the emergency treatment of stroke.<\/p>\n","protected":false},"author":1,"featured_media":8499,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-16874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017 - MabDesign<\/title>\n<meta name=\"description\" content=\"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017, for the emergency treatment of stroke.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017 - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017, for the emergency treatment of stroke.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-07T12:37:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png\" \/>\n\t<meta property=\"og:image:width\" content=\"133\" \/>\n\t<meta property=\"og:image:height\" content=\"60\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017\",\"datePublished\":\"2017-02-07T12:37:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/\"},\"wordCount\":116,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/\",\"name\":\"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017 - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png\",\"datePublished\":\"2017-02-07T12:37:56+00:00\",\"description\":\"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017, for the emergency treatment of stroke.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png\",\"width\":133,\"height\":60},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017 - MabDesign","description":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017, for the emergency treatment of stroke.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/","og_locale":"en_US","og_type":"article","og_title":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017 - MabDesign","og_description":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017, for the emergency treatment of stroke.","og_url":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/","og_site_name":"MabDesign","article_published_time":"2017-02-07T12:37:56+00:00","og_image":[{"width":133,"height":60,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png","type":"image\/png"}],"author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017","datePublished":"2017-02-07T12:37:56+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/"},"wordCount":116,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/","url":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/","name":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017 - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png","datePublished":"2017-02-07T12:37:56+00:00","description":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017, for the emergency treatment of stroke.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/Acticor-Biotech-72dpi.png","width":133,"height":60},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/acticor-biotech-secures-e15m-to-accelerate-the-clinical-study-of-act-017\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Acticor Biotech secures \u20ac1,5M to accelerate the clinical study of ACT-017"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=16874"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16874\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/8499"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=16874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=16874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=16874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}